Long‐term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease

Abstract

MMF was associated with a modest improvement in mRSS and was well tolerated in the treatment of dcSSc. Given the natural history of dcSSc where skin involvement can spontaneously improve, randomized, placebo-controlled studies are required to confirm whether improvement can be attributed to MMF therapy.